TuHURA has secured a US patent covering TBS-2025 and related VISTA-targeting antibody designs through February 2042. The intellectual property expansion follows FDA clearance of an early-stage AML study, but clinical efficacy and commercialization remain unproven.
SELLAS investors await event-driven Phase 3 AML results while SLS009 heads to AACR with preclinical pancreatic cancer combination data.
Orum plans an approximately 42-patient Phase 1 study of ORM-1153 after FDA cleared the CD123-targeting conjugate to deliver a GSPT1 protein degrader into AML cells.
FDA orphan drug status expands enzomenib’s ALL pathway as Sumitomo Pharma advances pivotal development in biomarker-defined acute leukemia.
MIRACLE reports a 37% blinded composite remission rate in relapsed AML, including patients who previously failed venetoclax treatment.
TSC-101 enters the Phase 3 ALLOHA-2 trial to test whether donor-derived TCR-T therapy can prevent AML and MDS relapse after transplant.
Find out how Blood Cancer United’s luveltamab access move could reshape rare pediatric AML drug rescue models.
Actinium’s science story is widening, but its balance sheet pressure is now impossible to ignore. ATNM-400 data may decide the next chapter.
Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.
Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.